A. Knight

发表

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations

D. Nordström, C. Kaiser, T. Pettersson, 2011, Rheumatology International.

Scalp Necrosis as a Late Sign of Giant-Cell Arteritis

M. Alimohammadi, A. Knight, 2013, Case reports in immunology.

Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis

C. Turesson, A. Knight, O. Börjesson, 2019, Scandinavian journal of rheumatology.

Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001.

J. Askling, A. Ekbom, L. Brandt, 2006, The Journal of rheumatology.

Are Farming and Animal Exposure Risk Factors for the Development of Granulomatosis With Polyangiitis? Environmental Risk Factors Revisited: A Case-control Study

H. Lindberg, A. Knight, J. Dahlqvist, 2020, The Journal of Rheumatology.

Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series

E. Baecklund, A. Knight, H. Hallenberg, 2013, Clinical Rheumatology.

Increased Risk of Autoimmune Disease in Families with Wegener’s Granulomatosis

S. Sandin, J. Askling, A. Knight, 2010, The Journal of Rheumatology.

Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci strati ﬁ ed by ANCA status

William J. Astle, Kenneth G. C. Smith, C. Wallace, 2019 .

Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA

K. Lindblad-Toh, R. Jonsson, Diana Ekman, 2021, Rheumatology.

Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter Study

H. Kautiainen, D. Nordström, J. Brun, 2012, The Journal of Rheumatology.

A case of systemic lupus erythematosus with C1q deficiency, increased serum interferon-α levels and high serum interferogenic activity.

L. Rönnblom, S. Kozyrev, M. Eloranta, 2019, Rheumatology.

Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study.

L. Rombo, S. Vene, A. Knight, 2016, Vaccine.

What is the significance in routine care of c-ANCA/PR3-ANCA in the absence of systemic vasculitis? A case series.

J. Askling, A. Ekbom, L. Brandt, 2008, Clinical and experimental rheumatology.

Risks and treatment related aspects of COVID-19 infection in patients with ANCA-associated vasculitis.

I. Gunnarsson, A. Bruchfeld, A. Knight, 2022, Scandinavian journal of rheumatology.

Late-onset neutropenia after rituximab in ANCA-associated vasculitis

I. Gunnarsson, A. Bruchfeld, V. Malmström, 2016, Scandinavian journal of rheumatology.

A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission

C. Turesson, E. Lindqvist, R. Vollenhoven, 2012 .

Occupational risk factors for Wegener's granulomatosis: a case–control study

S. Sandin, J. Askling, A. Knight, 2009, Annals of the rheumatic diseases.

Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis

A. Larsson, G. Serre, K. Skriner, 2018, Annals of the rheumatic diseases.

Fatal outcome of tick-borne encephalitis in two patients with rheumatic disease treated with rituximab.

G. Nordmark, E. Kumlien, A. Knight, 2017, Rheumatology.

Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide

P. Sparén, F. Granath, J. Askling, 2004, Annals of the rheumatic diseases.

Clinical and Epidemiological Studies of Wegener´s Granulomatosis

A. Knight, 2007 .

Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome

M. Höglund, J. Askling, E. Baecklund, 2015, The Journal of Rheumatology.

Cancer incidence in a population‐based cohort of patients with Wegener's granulomatosis

J. Askling, A. Ekbom, A. Knight, 2002, International journal of cancer.

Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine Clinical and Epidemiological Studies of Wegener ́ s Granulomatosis

A. Knight, Ann Knight, 2007 .

Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis – a prospective cohort study

A. Larsson, T. Saxne, J. Rönnelid, 2014, Arthritis Research & Therapy.

Pentraxin 3 in serum and synovial fluid of patients with rheumatoid arthritis with and without autoantibodies

A. Larsson, T. Saxne, J. Rönnelid, 2017, Scandinavian journal of rheumatology.

Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

S. Horton, M. Gianfrancesco, J. Yazdany, 2021, The Lancet Rheumatology.

Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis

G. Enblad, E. Baecklund, C. Sundström, 2019, Acta oncologica.

The Journal of Rheumatology Subtypes, Clinical Characteristics, and Outcome Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis:

M. Höglund, J. Askling, E. Baecklund, 2015 .

Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease.

S. Sandin, J. Askling, A. Knight, 2008, Arthritis and rheumatism.

FRI0163 Efficacy of The Biosimilar BOW015, Compared To Originator Infliximab, Initiated at Moderate and Severe Disease Activity Thresholds in Rheumatoid Arthritis

C. Costantino, M. Wyand, C. Lassen, 2016 .

Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies.

A. Larsson, J. Rönnelid, A. Knight, 2015, Rheumatology.

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission

C. Turesson, E. Lindqvist, R. V. van Vollenhoven, 2016, RMD Open.

High levels of interleukin-6 in rheumatoid arthritis joint fluids can stimulate local production of C-reactive protein resulting in elevated circulating levels.

A. Larsson, J. Rönnelid, A. Knight, 2021, Joint Bone Spine.

Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter Study

H. Kautiainen, D. Nordström, J. Brun, 2012, The Journal of Rheumatology.

Stratified genetic analysis reveals sex differences in MPO-ANCA-associated vasculitis

K. Lindblad-Toh, R. Jonsson, Diana Ekman, 2023, Rheumatology.